Evaluation of humoral immunity profiles to identify heart recipients at risk for development of severe infections: A multicenter prospective study

Abstract

Early immunologic monitoring of humoral immunity profiles proved useful for the identification of heart recipients who are at risk of severe infection.

Genetic and Functional Profiling of CD16-Dependent Natural Killer Activation Identifies Patients at Higher Risk of Cardiac Allograft Vasculopathy

“…Th T e strength h of the study is to provide d evide d nce that the identification of the CD CD16 profi f le Previous studies have identified CMV infection as a risk factor associated with the development of allograft vascular lesions 33,34 . In the present cohort, the FCGR3A-VV genotype was identified as a risk factor associated with viral infections.…”

Going beyond serology for stratifying the risk of CMV infection in transplant recipients

“…A retrospective analysis of liver recipients included in a clinical trial evaluating the effect of CMV-specific hyperimmune globulin prophylaxis on the prevention of disease and its complications suggested that HGG was associated to both the occurrence and the relapse of CMV disease after transplantation. 48 The results from a meta-analysis suggested that severe IgG HGG significantly increases the risk of CMV infection and is associated with higher 1-year all-cause mortality. 47 A recent cohort study of heart transplant recipients demonstrated that the presence of IgG HGG at 7 days after transplantation is a risk factor for CMV disease.…”

“…47 A recent cohort study of heart transplant recipients demonstrated that the presence of IgG HGG at 7 days after transplantation is a risk factor for CMV disease. 48 In addition, in a clinical trial the administration of two monoclonal antibodies in R − kidney recipients at the time of transplant and 1, 4, and 8 post-transplant weeks reduced the incidence of CMV infection, increased the time interval to CMV viremia and was associated with less CMV disease. 49 More recently, early monitoring of specific humoral immunity parameters was proven to be useful for the identification of lung recipients who are at risk of serious infections.…”

“…In fact, hypogammaglobulinemia (HGG), that it is common among transplant recipients receiving immunosuppressive regimens, has been recognized as a risk factor for post‐transplant CMV disease. A retrospective analysis of liver recipients included in a clinical trial evaluating the effect of CMV‐specific hyperimmune globulin prophylaxis on the prevention of disease and its complications suggested that HGG was associated to both the occurrence and the relapse of CMV disease after transplantation . The results from a meta‐analysis suggested that severe IgG HGG significantly increases the risk of CMV infection and is associated with higher 1‐year all‐cause mortality .…”

“…The results from a meta‐analysis suggested that severe IgG HGG significantly increases the risk of CMV infection and is associated with higher 1‐year all‐cause mortality . A recent cohort study of heart transplant recipients demonstrated that the presence of IgG HGG at 7 days after transplantation is a risk factor for CMV disease . In addition, in a clinical trial the administration of two monoclonal antibodies in R − kidney recipients at the time of transplant and 1, 4, and 8 post‐transplant weeks reduced the incidence of CMV infection, increased the time interval to CMV viremia and was associated with less CMV disease .…”